BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 32483919)

  • 1. Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Int J Rheum Dis; 2020 Jul; 23(7):868-875. PubMed ID: 32483919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC; Song GG
    Rheumatol Int; 2015 Dec; 35(12):1965-74. PubMed ID: 25994093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of tofacitinib and mavrilimumab in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    Int J Clin Pharmacol Ther; 2021 Aug; 59(8):557-565. PubMed ID: 33860755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Lee YH; Song GG
    Clin Drug Investig; 2020 Jan; 40(1):65-72. PubMed ID: 31602572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
    Lee YH; Song GG
    Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.
    Qu B; Zhao F; Song Y; Zhao J; Yao Y; Chen Y; Liao R; Fu L
    PLoS One; 2024; 19(6):e0305621. PubMed ID: 38905267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
    Sung YK; Lee YH
    Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials.
    Song GG; Bae SC; Lee YH
    Korean J Intern Med; 2014 Sep; 29(5):656-63. PubMed ID: 25228842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
    Qiu Q; Feng Q; Tan X; Guo M
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):547-554. PubMed ID: 31059310
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Song GG; Lee YH
    Clin Drug Investig; 2019 May; 39(5):421-428. PubMed ID: 30806969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.